Vimarsana
Biggest News Aggregation in the World

Mariposa Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mariposa Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mariposa Study Today - Breaking & Trending Today

MARIPOSA: Amivantamab, Lazertinib and Chemotherapy in Frontline EGFR-Mutant NSCLC - Vimarsana News

MARIPOSA: Amivantamab, Lazertinib and Chemotherapy in Frontline EGFR-Mutant NSCLC

Published: December 20, 2023

The panel reacts to the MARIPOSA trial, which looked at amivantamab, lazertinib, and chemotherapy in the front line in patients with EGFR-mutant non–small cell lung cancer.

Source: onclive.com
Related Topics:
Evolving Treatment ParadigmAdvanced NonSmall Cell Lung CancerNon Small Cell Lung CancerAdvanced Non Small Cell Lung CancerAdvanced NsclcNsclc TreatmentEgfr Mutant Lung CancerEgfr Mutated Lung CancerFirst Line TreatmentMariposa Study
COMING SOON: Amivantamab + Lazertinib Versus Osimertinib as 1L Treatment in EGFR-Mutated Advanced NSCLC: Primary Results From MARIPOSA - Vimarsana News

COMING SOON: Amivantamab + Lazertinib Versus Osimertinib as 1L Treatment in EGFR-Mutated Advanced NSCLC: Primary Results From MARIPOSA

Published: October 30, 2023

Expert oncologist Alex Spira, MD, PhD, FACP, shares his excitement for an upcoming program centered on the MARIPOSA study in advanced NSCLC following the ESMO 2023 annual meeting.

Source: onclive.com
Related Topics:
Lazertinib Versus OsimertinibMutated AdvancedPrimary Results FromNon Small Cell Lung CancerAdvanced NsclcMetastatic NsclcMariposa TrialMariposa StudyEgfr MutatedEgfr MutantCombination TherapyNovel TherapyEgfr TkiTyrosine Kinase InhibitorsMet InhibitorChrysalis StudyChrysalis TrialExon 20Egfr L858rEfficacy DataOverall SurvivalProgression Free SurvivalPfs DataCns DiseaseBrain Metastases